18F-FDG PET/CT监测默克尔细胞癌对新型程序性细胞死亡配体1抑制剂阿维鲁单抗的治疗反应
一例85岁左臂IIIA期默克尔细胞癌患者,术后8个月全身FDG PET/CT发现肝转移及腹部淋巴结转移,因高龄合并症多被认为不适合化疗而启用新型程序性细胞死亡配体1抑制剂阿维鲁单抗;4个周期后FDG PET/CT显示肝及淋巴结转移完全消退。全身FDG PET/CT可用于监测默克尔细胞癌多系统转移对主动免疫治疗的反应。
要点
- 85岁IIIA期默克尔细胞癌患者术后8个月出现肝及腹部淋巴结高代谢转移。
- 因高龄合并症被认为不适合化疗,启用程序性细胞死亡配体1抑制剂阿维鲁单抗。
- 4个周期后FDG PET/CT显示肝及淋巴结转移完全消退。
核心结论
- 全身FDG PET/CT可用于监测默克尔细胞癌多系统转移对主动免疫治疗的反应。
研究设计与样本
- 一例85岁左臂IIIA期默克尔细胞癌患者的病例报告。
主要发现
- 患者最初接受局部切除和腋窝淋巴结清扫,随后放疗。
- 术后8个月全身FDG PET/CT显示肝转移及腹部淋巴结转移呈明显高代谢。
- 因高龄和合并症被认为不适合化疗,启用新型程序性细胞死亡配体1抑制剂阿维鲁单抗。
- 4个周期后FDG PET/CT显示肝及淋巴结转移完全消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.
引用
- Eshghi N, Lundeen TF, MacKinnon L, et al. 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med. 2018. PMID: 29538029. doi:10.1097/RLU.0000000000002051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。